Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 119.00p 118.00p 120.00p 119.00p 119.00p 119.00p 0 07:46:45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 165.6 8.4 6.3 19.0 125.00

Cello Health PLC AGM Statement

08/05/2019 7:00am

UK Regulatory (RNS & others)


Cello Health (LSE:CLL)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Cello Health Charts.

TIDMCLL

RNS Number : 2801Y

Cello Health PLC

08 May 2019

FOR IMMEDIATE RELEASE 8 May 2019

Cello Health plc

("Cello" or the "Group")

AGM Statement

Cello Health plc (AIM: CLL), the global healthcare-focused advisory Group, announces that at the Annual General Meeting to be held later today Chairman Chris Jones will make the following statement:

"The Group has had a very good start to the year. For the first quarter, the Group has experienced good like-for-like net revenue and headline profit before tax growth. We are also confident regarding performance in the second quarter, and expect to report robust headline profit before tax growth for the first half of the year.

"At a segment operating level, Cello Health has had an excellent first quarter. In particular, the performances in our consulting businesses and in the US overall are notable. We expect the second quarter to continue this trend.

"Cello Signal has also made a solid start to the year in line with expectations.

"The Group's balance sheet remains strong, with better than expected cash conversion so far in 2019, continuing the strong cash conversion performance delivered in 2018. The Group continues to assess suitable acquisitive growth opportunities in the US.

"The Board is therefore confident of achieving a successful full year result in 2019, in line with expectations."

Enquiries:

 
  Cello Health plc                         020 7812 8460 
  Mark Scott, Chief Executive 
  Mark Bentley, Group Finance Director 
  Cenkos Securities plc                    020 7397 8900 
  Mark Connelly/Harry Hargreaves 
 
  Buchanan 
   Mark Court                              020 7466 5000 
  Jamie Hooper 
  Sophie Wills 
 
 

About Cello Health plc

We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, Germany and Asia, with hub offices in New York, Philadelphia, London, Berlin, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGMEAKSXEELNEFF

(END) Dow Jones Newswires

May 08, 2019 02:00 ET (06:00 GMT)

1 Year Cello Health Chart

1 Year Cello Health Chart

1 Month Cello Health Chart

1 Month Cello Health Chart
Your Recent History
LSE
CLL
Cello Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190717 09:00:25